Drug delivery has seen plenty of acquisitions—but they represent two basic philosophical approaches, represented most recently by Johnson & Johnson 's purchase of Alza Corp. (the we-need-to-develop-our-own-products point of view) [See Deal] and Inhale Therapeutic System Inc.'s acquisition of two privately-held firms (the we-can-grow-as-a-service-business perspective).
According to the first view, by the mid-1990s, Alza had simply run out of growth opportunities in drug delivery. The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?